全球藥品市場前景及投資研究報告-培訓課件外文版2024.5片仔癀

INDUSTRIES

&

MARKETSPharmaceuticals:

market

data&

analysisMarket

InsightsreportOctober2023MARKET

INSIGHTSThis

report

is

part

ofour

Market

Insights

productGainabetterunderstandingofmarketsacross190+

geographicalentities

–

onaglobal,

regional,country,

and/orstatelevel.

Accessourdatavia

webinterface,download(XLS,

PDF,PPT),or

reports.Benefitfromour48-hourcustomerservice

guarantee.?

10

sectors:

advertising&media,consumers,countries,digital

sector,finance,health,

industrialsector,mobility,andtechnology?

1,000+

markets,

e.g.,

FinTech,Food,or

Robotics?

KPIs,

e.g.,

revenue,marketshares,prices,andvolume?

Features:Compare

countries®ions,

change

currencies,

selectvisualizations,

and/or

customize

downloads?

Usecases:

sales

planning,

investment

decision

support,resourceallocation,andportfolio

management10sectors190+geographicalentities1,000+markets400+reportsFind

out

more

on:https://www.Goto

Market

Insightscom/outlook/3CHAPTER

1Overview?

Summary?

Market

definition

and

therapeutic

areas?

Key

takeaways?

Salesfigures?

Regional

comparison?

Drivers?

TrendsThe

Pharmaceuticals

marketis

one

of

the

main

pillars

of

the

health

marketsOverview:

management

summaryThepharmaceutical

industryisresponsible

forthe

research,

development,production,anddistributionof

medications.

ThePharmaceuticalsmarket

showsIngeneral,

thePharmaceuticalsmarket

ishighly

regulated.

Itis

usuallycharacterized

bystrictapproval

processes

andstrong

patentlegislation.solid

growth,

which

ismainly

driven

byinnovative

drugsandanincreasing

demand

Regulations,

theavailabilityand

approval

of

drugs,andtheperiod

of

exclusivityforhealthcare,

especially

inemerging

countries.vary

greatly

from

country

to

country.Compared

totherevenue

generated

byprescription

drugs,OTCpharmaceuticalsonly

playaminor

role.

Themarket

forprescription

drugs,foritspart,isdominatedbyoriginal

products.

Thismeans

thatthe

larger

number

ofOTCproducts,generics,andbiosimilars

sold

cannotcounterbalance

thesignificantlyhigherprices

oforiginal

products.Oncology

Drugsisbyfarthelargest

market.

Interms

of

regional

share,theU.S.dominate

the

market,

with

Europe,

Japan,

andChina

alsoplayingasignificantrole.Thedifferent

therapeuticareas

havebeen

affected

very

differently

bytheCOVID-19pandemic.

While

vaccinesagainstthevirusare

generating

additionalrevenue,

andthedevelopment

of

mRNA

drugshasreceived

aboost,most

pharmaceutical

fieldshavebeen

negatively

impacted,mainly

dueto

fewer

new

patientsand

barriers

toThecommercially

most

successful

drugs,theso-called

"blockbusters,"

eachgenerate

more

thanUS$1billion

ayear.

Sincesingle

productscanplayamajor

role,

healthcare

access.

Ingeneral,

theless

life-threatening

thecondition,thestrongercertain

markets

are

driven

byonly

asmall

numberof

drugs.Some

companies,

inturn,generate

asignificant

share

oftheirrevenue

withonly

ahandful

of

products.thenegative

effect.ThePharmaceuticals

market

is

characterized

bydisruptionsdueto

innovativedrugsandexpiring

patents.Research

and

development,

which

involves

large

costsaswell

ashigh

risks

and

considerable

uncertainties,

isthemainmarket

driver.5Sources:Market

Insights

2023The

Pharmaceuticals

market

covers

both

prescription

and

OTC

drugs

in

alltherapeutic

areasOverview:

market

definition

and

therapeutic

areas

(1/3)Definition

ofthePharmaceuticals

marketInscopeOutof

scopeThePharmaceuticals

market

covers

remedies

used

tocure,treat,prevent,

anddiagnose

diseases.

These

small

molecule

drugsor

biologic

medical

products

maybecalled

drugs,medications,

or

medicines.

Prescription

drugsandover-the-counter

(OTC)

drugsarebothincluded.

Depending

on

theregulations

ineachcountry,these

productsare

provided

bypharmacies,

hospitals,physicians,and/ordrugstores,

and/ortheycanbeboughtelsewhereThismarket

includes:Thismarket

excludes:?Prescription

andover-the-counter(OTC)drugs?Veterinary

drugs?Medical

devices?Smallmolecule

drugsandbiologicmedical

products?Profitof

wholesalers,

pharmacies,hospitals,and

clinicsThePharmaceuticals

market

is

organized

into

markets

thatcover

drugsusedinspecificmedical

fields,i.e.,medicines

foraspecific

disease

or

acertain

typeofmedicine.

Theyincludeoriginal

brands,biosimilars,

generics,

and

orphan

drugs.TheOtherPharmaceuticals

market

provides

information

onadditionalspecialtiesthatare

notcovered

bythemainmarkets.?Vaccines?Originalbrands,biosimilars,

andgenericsMarket

valuesrepresent

therevenues

generated

bymanufactureprices

paid

toprimary

vendors,

either

directly

or

throughdistributionchannels

(excludingVAT).

Reported

market

revenues

includespendingbyconsumers

(B2C),companies(B2B),

andgovernments

(B2G).6Notes:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Sources:The

Pharmaceuticals

marketis

divided

into

16

markets

focusing

on

differenttherapeutic

areasOverview:

market

definition

and

therapeutic

areas

(2/3)Oncology

DrugsAnti-DiabetesDrugsAnti-Rheumatic

DrugsCOVID-19

Vaccines?

Treatment

fordifferent

typesof?

Drugsto

treat

diabetes

mellitus(oral?

Drugs

to

treat

rheumatism?

COVID-19

vaccines?

mRNA-based

vaccines?

Viral

vector

vaccinescancerintakeand

injections)?

Steroidal

(corticosteroids)

andnon-?

Chemotherapeutic

agents?

Immuno-oncology

drugs?

Oncology

orphan

drugs?

Insulinsteroidal

anti-rheumatics?

Non-insulinotropic

anti-diabeticdrugs

?

Disease-modifying

anti-rheumaticdrugs(DMARDs)?

Tumor

necrosis

factor(TNF)inhibitorsOtherVaccinesDermatology

DrugsAntiviralDrugs?

HIVImmunosuppressants?

Vaccines

againstinfectious

diseases?

Prophylacticandtherapeuticvaccines?

FluvaccinesDrugsto

treat

diseases

related

to

skin,nails,hair,and

genital

membranes??

Drugsto

suppress

the

immuneresponse?

Hepatitis

Band

hepatitisC?

Ebola?

Steroids

suchascorticosteroids?

Immunosuppressants

to

treat

auto-(topical

and

systemic)immune

diseases,

suchas

psoriasis?

COVID-19?

Topical

antihistamines?

Antifungals?

Anti-rejection

drugs7Sources:Market

Insights

2023The

Pharmaceuticals

marketis

divided

into

16

markets

focusing

on

differenttherapeutic

areasOverview:

market

definition

and

therapeutic

areas

(3/3)Bronchodilator

DrugsSensory

OrganDrugs?

Ophthalmologicals?

OtologicalsAnti-HypertensiveDrugsAnti-Coagulants?

Short-term

andlong-term?

Drugsto

treat

highblood

pressure?

Pulmonary

hypertension?

Blood

clotting

inhibitorsbronchodilators?

Inhalationpowder

(aerosolized

or

dry),but

alsonebulizers,

intravenousadministration,andoral

intake?

Bronchodilator

combinationsAnti-Fibrinolytic

Drugs?

Inhibitorsoffibrinolysis?

Drugsto

treat

hemophiliaMultipleSclerosis

Drugs?

Drugsto

treat

multiplesclerosis?

Monoclonal

antibodies?

ImmunosuppressantsLipid-Lowering

AgentsOtherPharmaceuticals?

Psychotropic

drugs?

Gastroenterology?

Coldandcoughremedies?

Antibiotics?

Anti-hyperlipidemics?

Drugsto

treat

highlevels

of

lipidsinthe

blood?

Cholesterol-lowering

drugs?

Women's

health?

Analgesics8Sources:Market

Insights

2023Despite

the

fast

growth

of

the

Vaccines

market,

Oncology

Drugs

still

generatedby

far

the

most

revenue

in

the

Pharmaceuticals

market

in

2022Overview:

key

takeawaysWorldwide

Pharmaceuticals

revenue

inbillionUS$b

in2022Keytakeaways?

In2022,

thePharmaceuticals

market

generated

total

revenues

ofUS$1,098.5OncologyDrugs8.2%billion

worldwide.?

Accountingfor8%

of

the

Pharmaceuticals

market,

Oncology

Drugswas

thelargest

market

in2022.Anti-DiabetesDrugsOtherPharmaceuticals3.2%?

In2022,

the

second

largest

market

was

Vaccines,

with

arevenue

ofUS$102.90billion

(5%),

followed

bytheAnti-Diabetes

Drugs,with

amarket

shareof

3%

and

arevenue

of

US$57.69

billion.21.4%Anti-RheumaticDrugs2.9%?

TheUnitedStates(US$589.00

billion)andChina

(US$117.40

billion)

accounted

for5.1%0.9%thehighest

revenues

within

thePharmaceuticals

market

in2022.Vaccines1.1%1.4%3.2%0.4%0.8%1.5%DermatologicalDrugsAntiviralDrugsImmunosuppressantsBronchodilatorDrugsSensoryOrgansDrugs1.1%1.3%Lipid-Lowering

AgentsMultipleSclerosisDrugsAnti-Fibrinolystics

Drugs2.0%Anti-CoagulantsAnti-HypertensiveDrugs9Sources:Market

Insights

2023The

strong

andsteady

growth

of

the

Pharmaceuticals

market

is

driven

byinnovative

drugs

and

has

also

been

recently

boosted

by

vaccinesOverview:

sales

figures(1/5)Worldwide

Pharmaceuticals

revenue

inbillionUS$1,477.91,388.41,305.81,233.21,169.41,115.01,098.51,051.1932.0917.4883.8848.4821.8201620172018201920202021202220232024202520262027202810Sources:Market

Insights

2023The

revenue

in

the

Oncology

Drugs

market

is

expected

to

grow

significantly

overthe

next

few

years

whereas

revenue

from

COVID-19

vaccines

may

decreaseOverview:

sales

figures(2/5)Oncology

Drugsrevenueinbillion

US$Anti-DiabetesDrugsrevenueinbillion

US$Anti-Rheumatic

Drugsrevenueinbillion

US$COVID-19

Vaccinesrevenueinbillion

US$+13.9%(1)361.6165.22022+5.5%(1)89.8-26.3%(1)-2.3%(1)65.363.857.750.110.2202820222028202220282022202811

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Forecasted

revenues

in

the

markets

Immunosuppressants

and

DermatologyDrugs

show

high

growth

ratesOverview:

sales

figures(3/5)OtherVaccinesrevenueinbillion

US$Dermatology

Drugsrevenueinbillion

US$AntiviralDrugsrevenueinbillion

US$Immunosuppressantsrevenueinbillion

US$14.4%(1)89.3+9.3%(1)-3.2%(1)66.564.152.939.139.9+10.1%(1)30.717.22022202820222028202220282022202812

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023While

most

markets

are

expected

to

grow

by

2028,

revenues

from

Anti-Hypertensive

Drugs

are

forecasted

to

remain

relatively

unchangedOverview:

sales

figures(4/5)Bronchodialtor

Drugsrevenueinbillion

US$Sensory

OrganDrugsrevenueinbillion

US$Anti-HypertensiveDrugsrevenueinbillion

US$Anti-Coagulants

revenueinbillion

US$+6.7%(1)41.7+4.0%(1)+5.2%(1)37.236.129.528.226.7-0.4%(1)22.622.12022202820222028202220282022202813

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Growth

projections

in

most

markets

of

the

Pharmaceuticals

market

remainmoderate

until

2028Overview:

sales

figures(5/5)Anti-Fibrinolytic

Drugsrevenueinbillion

US$MultipleSclerosis

Drugsrevenueinbillion

US$Lipid-LoweringAgents

revenueinbillion

US$OtherPharmaceuticals

revenueinbillion

US$+3.7%(1)537.7432.8+1.0%(1)+4.0%(1)23.422.120.516.2-0.5%(1)8.28.02022202820222028202220282022202814

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023In

2022,

the

United

States

and

China

showed

the

highest

revenues

in

thePharmaceuticals

marketRegional

comparison:

worldwide

comparisonRevenue

comparison

inbillionUS$

in2022Revenue

sharesin2022United

States589.0Asia22%ChinaJapan117.746.835.929.326.318.818.3GermanyUnited

KingdomFrance59%17%AmericasEuropeCanadaBrazil1%1%Italy

15.9Spain

14.8AfricaAustralia&Oceania15Sources:Market

Insights

2023More

than

half

of

the

worldwiderevenue

of

the

Pharmaceuticals

market

isgeneratedin

the

United

StatesRegional

comparison:

AmericasRevenue

of

the

top

countriesinbillionUS$+5.2%(1)798.2589.0+5.5%(1)+5.8%(1)+4.3%(1)+2.9%(1)25.825.718.818.36.78.74.25.02022202820222028202220282022202820222028United

StatesCanadaBrazilMexicoArgentina16

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023InEurope,

most

revenue

in

the

Pharmaceuticals

market

is

generatedinGermany

and

the

United

KingdomRegional

comparison:

EuropeRevenue

of

the

top

countriesinbillionUS$+5.7%(1)+5.0%(1)+4.4%(1)+4.5%(1)50.1+3.4%(1)39.435.933.929.326.320.718.215.914.82022202820222028202220282022202820222028GermanyUnited

KingdomFranceItalySpain17

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Inthe

Asia-Pacific

region,

most

of

the

revenue

in

the

Pharmaceuticals

market

isgeneratedin

China

and

JapanRegional

comparison:

Asia-PacificRevenue

of

the

top

countriesinbillionUS$+5.9%(1)165.9117.7+5.0%(1)62.8+6.4%(1)+6.5%(1)46.8+6.3%(1)17.516.312.911.213.49.32022202820222028202220272022202820222028ChinaJapanSouthKoreaIndiaAustralia18

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023The

pharmaceuticals

market

is

mainly

driven

by

an

increasing

number

ofpatients,

higher

healthcare

expenditures,

and

R&Dof

novel

drugsDrivers

(1/8)More

patientsHealthcare

expenditureResearch

andDevelopmentWhile

the

casenumbers

of

existing

diseases

suchasdiabetesincrease,

new

diseases

arealsoemerging,with

COVID-19

as

astrikingexample.

Bothdevelopments

haveledtoanincreased

demand

formedicines.Access

to

healthcare

differssignificantly,but

indeveloping

countries,

healthcareexpenditures

haveincreased

considerably.Innovation

playsacentral

role

inthepharmaceuticalindustry.Successful

developments

may

besold

athighprices

untiltheirpatentsexpire

and

competition

setsin.19Newly

emerging

diseases

and

an

increasing

prevalence

of

existing

illnesses

leadto

an

increased

demand

for

medicinesDrivers

(2/8)Numberofdiabetespatients(ages20-79)

inmillionsDrivers

ofthepharmaceutical

industrycanbetraced

tothe

rising

numberofpatientsresulting

from

agrowing

world

population,newly

emerging

diseases

(suchasCOVID-19),

and

thehigherprevalence

of

existing

diseases.

Astriking

example

istheworldwide

prevalence

of

diabetesmellitus,

which

shows

adramaticincreasefrom

6.4%

in2012

to9.5%

in2022(1).

Putanotherway,

nearly

one

outof10

peoplesuffersfrom

diabetes.500World450400350Withtheincrease

indiabetes

patients,strong

regional

differences

canbeobserved.While

casenumbers

incountries

suchastheU.S.

haveonlymoderately

increased,thenumber

ofpatientsisrapidlyincreasing

indeveloping

regions

of

theworld.

InChina,

forexample,

thenumber

ofdiabetes

patientshasnearly

tripledover

the

lastdecade.300100ChinaU.S.Based

onthelinkbetween

obesity

and

diabetes,

thistendency

canbeattributedtoanincrease

in

sedentary

lifestyles.

Otherrisk

factorshavebeen

linkedtodiet,workroutines,

and

airpollution

exposure.

Theincrease

inpatientnumbers

hasfueledboththeneed

forexisting

medicines

and

thedevelopment

of

new

ones.5002012

2013

2014

2015

2016

2017

2018

2019

2020

2021

202220

Notes:Sources:(1)

Diabetes

patients

aged20-79

years.based

onWorldDiabetes

Federation,

WorldBankAccess

to

healthcare

differs

significantly,

but

developing

countries

haveconsiderably

increased

healthcare

expendituresDrivers

(3/8)Total

healthcare

expenditure

inbillionUSDAroundtheworld,

there

arewide

disparities

inaccess

to

healthcare

with

well-functioningand

established

systems,

e.g.,inNorth

America

andEuropeon

theonehand

andmanypartsof

the

world

with

onlylimited

access

ontheother.

However,inmanydeveloping

countries,

thesituationisimproving

rapidly.+174.4%2,190798Oneway

tomeasure

improved

access

tohealthcare

istoexamine

totalhealthcareexpenditure.

In2021,

atremendous

sumofUS$10.4

trillion

was

spentonhealthcare

worldwide.

Theexpected

increase

tomore

thanUS$3

trillion

by2027means

adoublingwithinadecade

compared

toUS$7.9

trillion

in2017.Alargecontribution

tothisgrowth

comes

from

rapidlydeveloping

regions

of

theworld,

e.g.,

LatinAmerica

(Brazil

inparticular)andAsia.InIndia,healthcarespendingisexpected

toalmost

doublewithin

adecade(2017-2027).

InChina,enormous

growth

rate

isexpected

andisprojected

toresult

inavalueofmore

thanUS$2

trillion

in2027.+62.2%317+97.8%195185942017China20272017202720172027IndiaBrazil21Sources:

Currenthealth

expenditure:based

onWHOand

national

statistical

offices;

GDP:based

onIMF;population:based

onUNDESAand

national

statistical

officesPharmaceutical

companies

spend

about

one

quarter

of

their

revenues

on

R&DDrivers

(4/8)Innovativedrugsarethemaindriver

of

the

pharmaceutical

industry.Companiesspend

onaverage

more

thanaquarteroftheirrevenues

ontheresearch

anddevelopment

ofnew

therapies

inthe

fightagainst

disease.

Thousandsofcomponents

arebeing

tested,but

only

very

few

prove

effective

againstamedicalcondition

andmakeitthroughallclinical

phases.

Thisputsthecompanies

athighrisk.Projected

clinicaldevelopmentspend

by

therapeutic

category

inbillionUS$(1)OncologyCentral

nervous

systemImmunomodulatorsMusculoskeletalCardiovascular8227Inthe

hunt

forvaccines

againstthe

COVID-19

virus,the

whole

world

witnessed

howafew

companies

were

ableto

develop

the

next

blockbuster

drugs,e.g.,BioNTech/Pfizer

and

Moderna,

while

others

failed,e.g.,CureVac.

Also,AstraZeneca’s

vaccineexemplified

how

the

reporting

of

serious

sideeffectsdamaged

the

reputation

of

aproduct.1614According

toEvaluatePharma,more

than

US$200

billion

arespent

onR&D

inthepharmaceutical

industry.Oncology,

which

isthelargest

market

interms

ofrevenue,alsotakesthetopspotinexpenditures

according

totherapeuticcategory.

Whileabout37%

oftheclinicaldevelopment

spendis

targeted

atnew

cancer

treatments,the

second

largest

category,

central

nervous

systems,

only

contributesabout12%.14Gastro-IntestinalTotal1321922

Notes:(1)

considering

products

in

USclinical

development

(phase

I-III)Sources:

EvaluatePharmaVision,

2020Pharmaceutical

R&D

is

at

the

forefront

of

the

fight

against

the

COVID-19pandemicDrivers

(5/8)Vaccines

playacrucial

role

infighting

viruses

thatcausediseases

suchasCOVID-19.

Share

or

respondentswith

littletrustinvaccination(1)Atthesame

time,some

people

havelittletrustinvaccines.

TheGlobal32%Consumer

Survey

reveals

thattheskepticism

towards

vaccinesis

strikinglydifferentfrom

country

to

country.

While

inMainlandChina,

only

oneout

often

respondentshadlittletrustinvaccines,

most

skeptics

outoftheselected

countries

lived

inIndia.TheCOVID-19

pandemichasled

toanew

impulseinpharmaceutical

R&D.

Theexceptionally

rapiddevelopment

of

several

highlyeffective

vaccines

changedthecourse

ofthepandemic.

Even

though

themost

dramatic

phasemightseem

to

beover,

theviruscontinuestospread.

Meanwhile,

vaccine

R&Dis

carried

outinordertoadapttheagentsto

theever-mutating

virus.23%22%21%19%18%16%13%While

themedical

protection

intheform

of

vaccinesis

generally

regarded

astheideal

approach,antiviraldrugsare

animportantbuildingblock

inthefight

againstthe

pandemic.

A

mere

two

years

afterthe

discovery

of

the

virus,thefirstproductsentered

themarket.

Antiviraldrugssuchas

Pfizer’s

Paxlovidpromise

tolower

therisk

of

hospitalization

and

death,byabout89%

andseveral

new

drugsthatreducethelikelihood

of

hospitalizationsand

death

arecurrently

indevelopment.10%ChinaUKSpainItaly

Germany

BrazilU.S.FranceIndia(Mainland)23

Notes:Sources:(1)

“I

have

little

trustin

the

safety

ofvaccinations.”;

China

(Mainland):

n=24,172;

U.K.:

n=15,206;

Spain:

n=12,206;

Italy:

n=12,198;

Germany:n=33,166;

Brazil:n=12,176;

USA:n=45,650;

France:n=12,198;

India:

n=24,182ConsumerInsights

2023;

Pfizerpressrelease;Chemical

&Engineering

News/Research

&

development

spending

in

the

Pharmaceuticals

market

is

exhibitinganincreasing

trend

with

a

CAGR(1)

of

+5%

from2016

to

2028Drivers

(6/8)R&D

SpendDevelopmentinbillionUS$29730025020015010050286274+5%(1)2632522402292192001841801711640201620172018201920202021202220232024202520262027202824

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Research

&

development

spending

shares

indicate

significant

competitionamong

the

major

playersDrivers

(7/8)R&D

Spendas

Share

ofRevenue

in2022R&D

SpendShares

by

biggestplayersin2022315%

4%4%5%4%3%6%25233%22226%3%3%212019182%16111152%AstraZenecaMerck

&Co.RocheEliLillyOtherAbbVieGilead

SciencesGlaxoSmithKlineNovartisPfizerBristol

Myers

SquibbNovartisGlaxoSmithKlineSanofiAstraZenecaJohnson

&JohnsonPfizerBristol

Myers

SquibbEliLillyJohnson

&JohnsonMerck

&Co.RocheSanofiAbbVieGilead

Sciences25

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Research

on

mRNA

drugs

promises

to

take

the

fight

against

a

wide

range

ofdiseases

to

a

new

levelDrivers

(8/8)Thescientificterm

mRNA,short

formessenger

RNA(1),hasbecome

abuzzword

thatisassociated

with

highhopes.

Research

aboutRNA-based

drugshadbeen

ongoingforafew

decades

when

attheendof

2020,

twohighlyeffective

COVID-19

vaccines,Comirnaty

bei

BioNTec/Pfizer

andSpikevax

byModerna,

emerged

asthefirstlarge-scale

applications.VaccinesCancerThemolecule

mRNA

transportsDNAinformation.

When

introduced

intocertaincells

inthe

body,proteinsare

produced

according

to

thisgenetic

sequence..

Thisabilityto

provide

ablueprint

forthe

creation

of

proteins

hasthe

potential

tobeused

inalargerangeof

therapeuticareas

thatgofarbeyond

vaccines

andincludeoncology,

psoriasis,

and

HIV.Alzheimer’sPsoriasisdiseasemDYet,

thisprocess

comes

with

anumberof

challenges.

IntroducingthemRNAmolecules

into

the(right)

cells

is

impeded

bythefactthattheyare

impermeable

tothe

cell

membrane

unlessasuitablevehicle

isused.

When

on

topof

themembrane,

unprotected

mRNA

degrades

over

time.

So,aprotective

coating

with

adifferent

substancehasto

beengineered.

Withinnovative

approaches,

researchersaretacklingthese

challenges

andhopeto

usher

inanew

era

of

therapies

forpatients.Osteo-arthritisMalariaHIV26

Notes:(1)

RNA

=ribonucleic

acidInthe

pharmaceuticals

industry,

several

trends

about

digitization

andconsumerbehavior

have

been

observedTrends(1/4)Onthe

following

slides,several

trendsinthepharmaceutical

industryarediscussed.Preference

ofalternative

healingmethods(1)24%23%?

Digitization

isabouttorevolutionize

established

structures

inhealthcare.?

Purchases

ofpharmaceuticals

areshiftingmore

and

more

toonlinechannels.?

Naturalpharmaceuticals

promise

alternatives

totraditionalproducts.21%20%19%19%17%15%Thedemand

foralternativeapproaches

isalsoreflected

inthe

dataoftheGlobal

Consumer

Survey.

Inthe

United

States,aboutone

outof

fiverespondentsprefers

alternative

healingmethods

toconventional

medicine.

Whereas

inmost

oftheselected

countries,

women

prefer

alternative

healing

methods,

thepreferencebygender

isreversed

inMainlandChina.13%11%China(Mainland)GermanyIsraelUnited

KingdomU.S.MaleFemale27

Notes:Sources:(1)

“I

preferalternative

healing

methods

toconventional

medicine.”;

China

(Mainland):

n=24,172;

Germany:n=33,166;

Israel:

n=2,086;

U.K.:

n=15,206;

USA:n=45,650ConsumerInsights

2023Digital

medical

services

are

used

bya

large

majority

across

manydifferentcountriesTrends(2/4)Digital

medicalservicesusers(1)Datafrom

theGlobal

Consumer

Survey

shows

the

highpenetration

ofusers

ofdigitalmedical

services.

Even

thoughthisdata

only

shows

theshareamong

internet

user